European trials with total mesorectal excision

Area of Science:

• Oncology
• Surgical Oncology
• Clinical Trials

Background:

• Rectal cancer surgery outcomes vary significantly, with high local recurrence linked to nonstandardized procedures.
• Preoperative radiotherapy improved survival in the Swedish Rectal Cancer Trial (SRCT), but many adjuvant therapy studies lacked surgical standardization and quality control.
• Total mesorectal excision (TME) is now the standard surgical approach in Europe, necessitating re-evaluation of adjuvant therapies.

Purpose of the Study:

• To examine European trials utilizing standardized total mesorectal excision (TME) for rectal cancer.
• To assess the feasibility of conducting large, multicenter trials with rigorous quality control for surgery and pathology in rectal cancer treatment.

Main Methods:

• Analysis of European clinical trials that intentionally incorporate TME surgery.
• Review of interim analyses from ongoing trials, focusing on those with quality control of surgical technique and pathological examination.

Main Results:

• Most European TME trials are ongoing with insufficient follow-up for definitive results, except for interim analyses.
• The Dutch TME trial demonstrated the feasibility of large-scale, multicenter trials with integrated surgical and pathological quality control.

Conclusions:

• Standardized TME surgery has improved local control and survival in rectal cancer treatment.
• Future adjuvant therapy studies must be based on a foundation of standardized, high-quality TME surgery and pathology.
• Multicenter trials with robust quality control are essential for advancing rectal cancer treatment strategies.